- Home
- SCNX vs ENLV Comparison
SCNX vs ENLV Comparison
Compare SCNX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | ENLV |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 26.6M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | SCNX | ENLV |
|---|---|---|
| Price | $0.55 | $0.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.8M | ★ 11.5M |
| Earning Date | 11-13-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $653,391.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.88 | N/A |
| 52 Week Low | $0.46 | $0.83 |
| 52 Week High | $8.19 | $2.10 |
Technical Indicators
Market Signals| Indicator | SCNX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 39.09 |
| Support Level | $0.60 | $0.89 |
| Resistance Level | $0.75 | $1.25 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 8.45 | 4.23 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.